Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470378 | 1.00 | KEAP1 (0.54) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL13303750 | 1.00 | KEAP1 (0.54) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4479994 | 0.99 | KEAP1 (0.52) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4620093 | 0.99 | KEAP1 (0.52) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4481649 | 0.97 | CHRM2 (0.50) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4188621 | 0.89 | KEAP1 (0.52) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4889393 | 0.84 | KEAP1 (0.50) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4471557 | 0.84 | CHRM2 (0.51) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4617494 | 0.84 | CHRM3 (0.52) | KEAP1NFE2L2CHRM3 | |
| Hydrochloric Acid SCHEMBL4479113 | 0.83 | CHRM2 (0.50) | KEAP1NFE2L2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-09 | — | — | US | disclosed |
| US-7446123-B2 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-04 | — | — | US | disclosed |
| US-20060287380-A1 | Azabicyclo Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-21 | — | — | US | disclosed |
| EP-1620087-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004089364-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | KEAP1 1651/4885NFE2L2 4207/4885CHRM2 3/4885 |
| US-20060287380-A1 | Azabicyclo Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | KEAP1 2173/4885NFE2L2 4059/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.